JP2021511054A5 - - Google Patents

Info

Publication number
JP2021511054A5
JP2021511054A5 JP2020540347A JP2020540347A JP2021511054A5 JP 2021511054 A5 JP2021511054 A5 JP 2021511054A5 JP 2020540347 A JP2020540347 A JP 2020540347A JP 2020540347 A JP2020540347 A JP 2020540347A JP 2021511054 A5 JP2021511054 A5 JP 2021511054A5
Authority
JP
Japan
Prior art keywords
item
hpv
peptide
pool
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020540347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511054A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000131 external-priority patent/WO2019145792A1/en
Publication of JP2021511054A publication Critical patent/JP2021511054A/ja
Publication of JP2021511054A5 publication Critical patent/JP2021511054A5/ja
Priority to JP2025093322A priority Critical patent/JP2025131713A/ja
Pending legal-status Critical Current

Links

JP2020540347A 2018-01-24 2019-01-23 Hpv免疫療法 Pending JP2021511054A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093322A JP2025131713A (ja) 2018-01-24 2025-06-04 Hpv免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862621279P 2018-01-24 2018-01-24
US62/621,279 2018-01-24
PCT/IB2019/000131 WO2019145792A1 (en) 2018-01-24 2019-01-23 Hpv immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093322A Division JP2025131713A (ja) 2018-01-24 2025-06-04 Hpv免疫療法

Publications (2)

Publication Number Publication Date
JP2021511054A JP2021511054A (ja) 2021-05-06
JP2021511054A5 true JP2021511054A5 (enExample) 2022-01-31

Family

ID=67395339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020540347A Pending JP2021511054A (ja) 2018-01-24 2019-01-23 Hpv免疫療法
JP2025093322A Pending JP2025131713A (ja) 2018-01-24 2025-06-04 Hpv免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093322A Pending JP2025131713A (ja) 2018-01-24 2025-06-04 Hpv免疫療法

Country Status (7)

Country Link
US (1) US20210046114A1 (enExample)
EP (1) EP3743436A4 (enExample)
JP (2) JP2021511054A (enExample)
CN (1) CN111868074A (enExample)
AU (2) AU2019213286A1 (enExample)
CA (1) CA3088837A1 (enExample)
WO (1) WO2019145792A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115867295A (zh) * 2020-03-23 2023-03-28 昆士兰医学研究所理事会 用于靶向hpv感染细胞的组合物和方法
WO2025088530A1 (en) * 2023-10-24 2025-05-01 Treadwell Therapeutics T cell receptors and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US20040171081A1 (en) * 2001-11-23 2004-09-02 Abraham Mittelman Antigens
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
WO2004011650A2 (en) * 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004105681A2 (en) * 2003-04-28 2004-12-09 Innogenetics N.V. Cd4+ human papillomavirus (hpv) epitopes
WO2005063286A1 (en) * 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
AU2005222776A1 (en) * 2003-12-31 2005-09-29 Genimmune N.V. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
CL2008000249A1 (es) * 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
US8969542B2 (en) * 2007-05-31 2015-03-03 Genimmune N.V. HPV polyepitope constructs and uses thereof
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
KR101749195B1 (ko) 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
CA2860914A1 (en) * 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
DK3271382T3 (da) * 2015-03-16 2020-05-04 Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
SG11201811442UA (en) * 2016-06-20 2019-01-30 Isa Pharmaceuticals B V Formulation of a peptide vaccine
KR20250136930A (ko) * 2018-03-06 2025-09-16 프레시전 인코포레이티드 사람 파필로마바이러스 백신 및 이의 용도

Similar Documents

Publication Publication Date Title
US20250188145A1 (en) Tcr and peptides
RU2721574C2 (ru) Вакцинная композиция против злокачественной опухоли
JP5934897B2 (ja) T細胞レセプターβ鎖遺伝子及びα鎖遺伝子
US20130028915A1 (en) Dendritic cell (dc)-vaccine therapy for pancreatic cancer
US20130217122A1 (en) Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
JP2012529283A (ja) 共有hla−b*0702エピトープの同定、最適化および免疫療法のための使用
JP7267014B2 (ja) 癌ワクチンにおける使用のためのpdl1ペプチド
JP2019520332A5 (enExample)
TWI374031B (enExample)
CN114302962B (zh) 特异性针对来源于ebv抗原的tcr构建体
Bright et al. SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma patients
Lyu et al. A novel and simple method to produce large amounts of recombinant soluble peptide/major histocompatibility complex monomers for analysis of antigen-specific human T cell receptors
CN111138521B (zh) 源自于afp抗原的短肽
JP2021511054A5 (enExample)
CN114853880A (zh) Wt1抗原特异性t细胞受体及其抗肿瘤用途
KR20110134482A (ko) Sox2 유래의 hla-a24결합성 암 항원 펩티드
CN106478797B (zh) 源自于sage1的肿瘤抗原短肽
JP6255360B2 (ja) 共有hla−b*0702エピトープの同定、最適化および免疫療法のための使用
NL2034657B1 (en) RCN1-derived TEIPP neoantigens and uses thereof
NL2034658B1 (en) TIMP3-derived TEIPP neoantigens and uses thereof
EP3055322B1 (en) Ubiquitinylated proteins
CN111138522B (zh) 衍生自afp的肿瘤抗原短肽
Yano et al. Correlation between Direct Binding Ability of SyntheticT. gondiiSAG1 Peptides to HLA-A2 Measured by a Sensor for Surface Plasmon Resonance and Antigenicity of the Peptides forT. gondii-Infected Cell-Specific CTL
CN112300261B (zh) 一种衍生自afp的肿瘤抗原短肽
CN110862449B (zh) 衍生自ssx的肿瘤抗原短肽